NCT00758628View on ClinicalTrials.gov

Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema.

PHASE4CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Diabetic Macular Edema

Interventions

DRUG

Bromefenac

Bromfenac BID 3 months

DRUG

Blink

Blink BID for 3 months

Trial Locations (1)

10075

Retina Eye Associates of New York, 140 East 80th Street New York, NY 10075

Sponsors

Lead Sponsor

Bp Consulting, Inc

All Listed Sponsors

lead

Bp Consulting, Inc

NETWORK

NCT00758628 - Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. | Biotech Hunter | Biotech Hunter